iifl-logo

Invest wise with Expert advice

By continuing, I accept the T&C and agree to receive communication on Whatsapp

sidebar image

The US facility of Eywa Pharma is purchased by Biocon for $7.7 million

4 Sep 2023 , 10:21 AM

Biocon announced on Saturday that one of its units had purchased the oral solid dosage manufacturing plant of Eywa Pharma Inc. in the US for $7.7 million (more than Rs 63 crore).

With effect from September 1, 2023, Biocon Generics Inc. has bought Eywa’s Cranbury factory, according to a statement from the Bengaluru-based business.

The facility is being purchased for a total of USD 7.7 million, it continued.

The facility’s current staff will move into Biocon Generics Inc. as part of the transaction.

The plant has the capacity to increase to 2 billion tablets/capsules annually.

‘The acquisition of this US FDA (US Food and Drug Administration) approved facility, our first in the US, will complement Biocon’s existing manufacturing capabilities and strengthen our foothold in the US,’ said Siddharth Mittal, managing director and chief executive officer of Biocon.

He noted that by diversifying its manufacturing infrastructure, the acquisition would also allow the company to add oral solid dosage capacities for new products quicker than initially anticipated and guarantee supply continuity.

For feedback and suggestions, write to us at editorial@iifl.com

Biocon - Wikipedia

Related Tags

  • Biocon
  • Eywa Pharma
sidebar mobile

BLOGS AND PERSONAL FINANCE

Read More

Invest wise with Expert advice

By continuing, I accept the T&C and agree to receive communication on Whatsapp

Knowledge Center
Logo

Logo IIFL Customer Care Number
(Gold/NCD/NBFC/Insurance/NPS)
1860-267-3000 / 7039-050-000

Logo IIFL Capital Services Support WhatsApp Number
+91 9892691696

Download The App Now

appapp
Loading...

Follow us on

facebooktwitterrssyoutubeinstagramlinkedintelegram

2025, IIFL Capital Services Ltd. All Rights Reserved

ATTENTION INVESTORS

RISK DISCLOSURE ON DERIVATIVES

Copyright © IIFL Capital Services Limited (Formerly known as IIFL Securities Ltd). All rights Reserved.

IIFL Capital Services Limited - Stock Broker SEBI Regn. No: INZ000164132, PMS SEBI Regn. No: INP000002213,IA SEBI Regn. No: INA000000623, SEBI RA Regn. No: INH000000248
ARN NO : 47791 (AMFI Registered Mutual Fund Distributor)

ISO certification icon
We are ISO 27001:2013 Certified.

This Certificate Demonstrates That IIFL As An Organization Has Defined And Put In Place Best-Practice Information Security Processes.